TMS therapy is one of the more effective options for depression that hasn’t responded to medication — and for TRICARE beneficiaries, it’s a covered benefit. The challenge isn’t awareness so much as eligibility. TRICARE requires specific clinical documentation before approving TMS, and the prior authorization process stalls most often not because a patient doesn’t qualify, but because the supporting records don’t capture the clinical picture clearly enough.
Understanding what TRICARE looks for before you start the process — and what documentation supports a clean submission — can save weeks of back-and-forth with your regional contractor. This article covers the eligibility criteria, the records you’ll need to gather, how the authorization process unfolds, and what options remain if an initial request is denied.
What TRICARE Covers for TMS Therapy
TRICARE covers TMS therapy as a treatment for major depressive disorder (MDD). Coverage is not currently extended to TMS for anxiety disorders, OCD, or PTSD as a standalone diagnosis under standard policy, though coverage guidelines do evolve. It’s worth confirming the current policy language at the time of your authorization request.
Coverage is never automatic. TRICARE requires prior authorization for TMS, which means treatment administered before approval will not be covered regardless of clinical outcome. This is a firm rule, not a gray area — it applies even when the authorization request is actively being processed.
Which TRICARE Plans Include TMS Coverage
TMS coverage applies under:
- TRICARE Prime
- TRICARE Select.
- TRICARE for Life
- TRICARE Reserve Select.
If you are enrolled in a managed care option or a regional variation, confirm coverage specifics with your regional contractor before starting the authorization process.
The Clinical Eligibility Requirements TRICARE Uses
TRICARE’s TMS eligibility criteria are grounded in the clinical evidence base for treatment-resistant depression. To qualify, you will generally need to meet all three of the following thresholds:
A Confirmed Major Depressive Disorder Diagnosis
Your MDD diagnosis must be documented in your medical records by a qualified provider. A diagnosis of bipolar disorder, persistent depressive disorder, or another mood condition will not typically meet this requirement — even when depressive symptoms are a prominent feature of that diagnosis. If there is diagnostic ambiguity in your records, that should be addressed with your provider before the authorization request is submitted.
Failure of at Least Two Adequate Antidepressant Trials
This is the most consequential eligibility threshold, and the one where documentation most often falls short. An “adequate” trial typically means each medication was taken at a therapeutic dose for a minimum of four to six weeks. That standard is precise, and the records need to reflect it.
Your provider will need to document the specific medications tried, the dosages used, the duration of each trial, and what the outcome was. Documentation that reads as “patient tried multiple antidepressants without success” — without specifics — is a reliable path to a request for additional information from the reviewer.
Continued Clinically Significant Symptoms
The documentation must reflect that depression is currently impairing your functioning — not that you had symptoms in the past that have since resolved. TRICARE reviewers look for objective evidence of current severity, typically measured using validated clinical assessment tools.
If You’re in Nevada: What TRICARE West Requires
Nevada falls under the TRICARE West region, administered by TriWest Healthcare Alliance. TriWest’s TMS policy, revised in September 2025, includes several requirements that differ from the East region — and one that applies equally to both but is worth stating clearly for Nevada patients.
PHQ-9 threshold. TriWest requires a documented baseline PHQ-9 score of at least 15 — indicating moderately severe depression — dated within the previous four weeks. This is a firm documentation requirement, not a general severity guideline.
Psychotherapy requirement. TriWest explicitly requires that a properly conducted episode of evidence-based psychotherapy — such as Cognitive Behavioral Therapy or Interpersonal Therapy — was attempted and did not produce an adequate response.
Antidepressant trial definition. TriWest defines nonresponse as less than 25% improvement in symptoms or scores, and requires the two failed medications to be from different pharmacologic classes — SSRIs, SNRIs, tricyclic antidepressants, bupropion, and mirtazapine are the classes named in the policy.
Each must have been taken at therapeutic doses for at least six weeks, unless clinically significant adverse effects made that duration impossible to complete.
Session authorization. TriWest approves up to 36 sessions delivered over 90 days for an initial authorization. Subsequent visits are not authorized under the same request — a patient would need to requalify under initial criteria if additional treatment is needed.
Adolescent coverage. As of November 2025, TriWest extended TMS coverage to beneficiaries aged 15 and older across all 26 TRICARE West states, including Nevada. The same four criteria apply to adolescent patients.
How the Prior Authorization Process Works
Prior authorization is typically initiated by your treating provider or the TMS clinic, not by the patient directly. The process generally follows these steps.
Step 1: Your provider documents medical necessity and assembles the relevant clinical records.
Step 2: The authorization request is submitted to your regional TRICARE contractor — Humana Military for TRICARE East, TriWest for TRICARE West.
Step 3: The contractor reviews the submission against current TRICARE medical policy criteria, assessing whether the documentation satisfies each eligibility threshold.
Step 4: A decision is issued — approval, denial, or a request for additional information.
Most prior authorization decisions are returned within 7 to 14 business days. Urgent requests supported by documented clinical justification can sometimes be processed more quickly.
In our clinical experience, requests that come back with a request for additional information are almost always cases where the medication trial history was underdocumented, or where current symptom severity wasn’t captured with assessment scores at the time of submission. Addressing both of those proactively is the most reliable way to avoid delays.
If TRICARE Denies Your TMS Request
A denial is not the end of the road. TRICARE has a formal appeals process, and many initial denials are overturned when documentation is strengthened or clarified. The denial notice will specify the reason, and your provider can use that directly to guide resubmission.
Common reasons for denial include insufficient evidence of prior treatment failure — medication trials documented without specifics on dose and duration — a diagnosis on file that doesn’t meet the covered indication, missing evidence of current severity, or an absent letter of medical necessity. Each of these is correctable.
In some cases, having a psychiatrist lead the medical necessity documentation improves the outcome of a formal appeal. Formal appeals must be filed within the timeframe specified in the denial notice. Patients can file an appeal directly; your provider can also support the process.
Getting the Authorization Right Before Treatment Starts
For most TRICARE beneficiaries, TMS coverage is achievable — provided the documentation tells a complete, accurate clinical story. The eligibility threshold is not unreachable. What delays most requests is incomplete medication trial records or missing evidence of current severity, both of which are correctable before the request goes in.
If you have questions about the process, your coverage, or whether TMS might make sense for you, contact Insight Therapy Solutions via call or text at 725 230 8526.
